Belabaci, Z.; Mose, L.; El-Taji, O.; Otmani, Z.; Hannouneh, Z.A.; Mohamad, I.; Zilli, T.; Mohamad, O.; Pervez, N.; Arafat, W.;
et al. Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review. Pharmaceuticals 2025, 18, 732.
https://doi.org/10.3390/ph18050732
AMA Style
Belabaci Z, Mose L, El-Taji O, Otmani Z, Hannouneh ZA, Mohamad I, Zilli T, Mohamad O, Pervez N, Arafat W,
et al. Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review. Pharmaceuticals. 2025; 18(5):732.
https://doi.org/10.3390/ph18050732
Chicago/Turabian Style
Belabaci, Zineddine, Lucas Mose, Omar El-Taji, Zina Otmani, Zein Alabdin Hannouneh, Issa Mohamad, Thomas Zilli, Osama Mohamad, Nadeem Pervez, Waleed Arafat,
and et al. 2025. "Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review" Pharmaceuticals 18, no. 5: 732.
https://doi.org/10.3390/ph18050732
APA Style
Belabaci, Z., Mose, L., El-Taji, O., Otmani, Z., Hannouneh, Z. A., Mohamad, I., Zilli, T., Mohamad, O., Pervez, N., Arafat, W., Vogl, U., & Shelan, M.
(2025). Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review. Pharmaceuticals, 18(5), 732.
https://doi.org/10.3390/ph18050732